Table 1.
Response Assessment by Modified RECIST (adapted from Lencioni et al8).
| Terminology | Description | |
|---|---|---|
| Target lesions | Complete response (CR) | Disappearance of any intratumoral arterial enhancement in all target lesions |
| Partial response (PR) | At least a 30% decrease in the sum of the diameters of viable (enhancement in the arterial phase) target lesions, taking as reference the baseline sum of the diameters of target lesions | |
| Stable disease (SD) | Any cases that do not qualify for either PR or PD | |
| Progressive disease (PD) | An increase of at least 20% in the sum of the diameters of viable (enhancement in the arterial phase) target lesions recorded since treatment started | |
| Non-target lesions | Complete response (CR) | Disappearance of any intratumoral arterial enhancement in all non-target lesions |
| Stable disease (SD) or incomplete response (IR) | Persistence of intratumoral arterial enhancement in one or more non-target lesions | |
| Progressive disease (PD) | Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions | |
| Additional recommendations | New lesion | A new lesion can be classified as HCC if its longest diameter is at least 1 cm and the enhancement pattern is typical for HCC. A lesion with atypical radiological pattern can be diagnosed as HCC by evidence of at least 1-cm interval growth. |
| Pleural effusion or ascites | Cytopathological confirmation of the neoplastic nature of any effusion that appears or worsens during treatment is required to declare PD | |
| Lymph nodes in the porta hepatis | Lymph nodes detected at the porta hepatis can be considered malignant if the lymph node short axis is at least 2 cm | |
| Portal vein thrombosis | Malignant portal vein thrombosis should be considered as a non-measurable lesion and thus included in the non-target lesion group |
Abbreviations: HCC, hepatocellular carcinoma; mRECIST, modified response evaluation criteria in solid tumors.